🌎 Super Micro Computer Initiated, Ingredion Upgraded, Cleveland-Cliffs Downgraded and more…
RJ Hamster
Ratings changes for Super Micro Computer, SSR Mining, CRISPR Therapeutics, Sanofi, NVIDIA, Signature Bank, Coinbase Global and more…Text “MarketBeat” to 68285 to get SMS breaking news alerts for stocks on your watchlist and other special reports.Learn More.
Unlock the Power of Tomorrow with the #1 Alternative Energy Stock! (ad)
Are you ready to invest in a brighter, greener future? Look no further – the #1 Alternative Energy Stock is here, leading the charge towards sustainable and profitable solutions! By clicking link you are subscribing to The Darwin Investor Network and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.
Apple Inc. (NASDAQ:AAPL) announced a quarterly dividend on Thursday, February 1st. Stockholders of record on Monday, February 12th will be paid a dividend of 0.24 per share by the iPhone maker on Thursday, February 15th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.53%. The ex-dividend date of this dividend is Friday, February 9th.
CEO Douglas J. Herrington sold 14,300 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $175.00, for a total value of $2,502,500.00. Following the sale, the chief executive officer now directly owns 499,831 shares in the company, valued at $87,470,425. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
CEO Mark Zuckerberg sold 34,398 shares of the company’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $469.69, for a total value of $16,156,396.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
CEO Mark Zuckerberg sold 34,398 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $473.32, for a total value of $16,281,261.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Air Products and Chemicals (NYSE:APD) was upgraded by analysts at Bank of America Co. from a “neutral” rating to a “buy” rating. They now have a $264.00 price target on the stock. This represents a 16.2% upside from the current price of $227.10.
Coinbase Global (NASDAQ:COIN) was upgraded by analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating. They now have a $80.00 price target on the stock. This represents a 52.3% downside from the current price of $167.60.
Entegris (NASDAQ:ENTG) was upgraded by analysts at Craig Hallum from a “hold” rating to a “buy” rating. They now have a $150.00 price target on the stock. This represents a 11.6% upside from the current price of $134.40.
Eversource Energy (NYSE:ES) was upgraded by analysts at Mizuho from a “neutral” rating to a “buy” rating. They now have a $62.00 price target on the stock, up previously from $54.00. This represents a 7.2% upside from the current price of $57.81.
Inogen (NASDAQ:INGN) was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.The current price is $9.98.
Ingredion (NYSE:INGR) was upgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “buy” rating. They now have a $135.00 price target on the stock, up previously from $122.00. This represents a 19.2% upside from the current price of $113.26.
Medpace (NASDAQ:MEDP) was upgraded by analysts at UBS Group AG from a “neutral” rating to a “buy” rating. They now have a $452.00 price target on the stock, up previously from $282.00. This represents a 15.8% upside from the current price of $390.34.
Manulife Financial (NYSE:MFC) (TSE:MFC) was upgraded by analysts at BMO Capital Markets from a “market perform” rating to an “outperform” rating. They now have a $35.00 price target on the stock, up previously from $31.00. This represents a 44.3% upside from the current price of $24.25.
Molina Healthcare (NYSE:MOH) was upgraded by analysts at Wells Fargo & Company from an “underweight” rating to an “equal weight” rating. They now have a $420.00 price target on the stock, up previously from $367.00. This represents a 5.7% upside from the current price of $397.44.
Outlook Therapeutics (NASDAQ:OTLK) was upgraded by analysts at Chardan Capital from a “neutral” rating to a “buy” rating. They now have a $3.00 price target on the stock. This represents a 538.3% upside from the current price of $0.47.
Similarweb (NYSE:SMWB) was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $10.00 price target on the stock, up previously from $6.00. This represents a 27.4% upside from the current price of $7.85.
Teradyne (NASDAQ:TER) was upgraded by analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating. They now have a $100.00 price target on the stock, up previously from $90.00. This represents a 2.2% downside from the current price of $102.20.
In the past year, AI has amazed us all with its achievements. It can predict weather, recommend winning stocks, create original art, write computer code, detect skin cancer – and, shockingly, it can do all these things better than most humans. But when you see its latest leap (revealed in on-location footage), you may want to pinch yourself!
Akamai Technologies (NASDAQ:AKAM) was downgraded by analysts at HSBC Holdings plc from a “hold” rating to a “reduce” rating. They now have a $96.00 price target on the stock, down previously from $109.00. This represents a 15.0% downside from the current price of $112.96.
Cleveland-Cliffs (NYSE:CLF) was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $20.00 price target on the stock, down previously from $21.50. This represents a 1.2% upside from the current price of $19.77.
Comcast (NASDAQ:CMCSA) was downgraded by analysts at Redburn Atlantic from a “buy” rating to a “neutral” rating. They now have a $44.00 price target on the stock, down previously from $50.00. This represents a 4.9% upside from the current price of $41.93.
Charles River Laboratories International (NYSE:CRL) was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating.The current price is $239.80.
Fastly (NYSE:FSLY) was downgraded by analysts at Craig Hallum from a “buy” rating to a “hold” rating. They now have a $20.00 price target on the stock. This represents a 19.1% upside from the current price of $16.79.
Generac (NYSE:GNRC) was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating.The current price is $117.84.
IPG Photonics (NASDAQ:IPGP) was downgraded by analysts at Citigroup Inc. from a “neutral” rating to a “sell” rating. They now have a $74.00 price target on the stock, down previously from $111.00. This represents a 17.1% downside from the current price of $89.25.
IQVIA (NYSE:IQV) was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating.The current price is $239.90.
Keysight Technologies (NYSE:KEYS) was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $170.00 price target on the stock, down previously from $184.00. This represents a 9.8% upside from the current price of $154.82.
Owens Corning (NYSE:OC) was downgraded by analysts at Evercore ISI from an “outperform” rating to an “in-line” rating. They now have a $154.00 price target on the stock, down previously from $163.00. This represents a 8.6% upside from the current price of $141.80.
Snowflake (NYSE:SNOW) was downgraded by analysts at HSBC Holdings plc from a “buy” rating to a “hold” rating. They now have a $214.00 price target on the stock, up previously from $212.00. This represents a 7.3% downside from the current price of $230.76.
Sony Group (NYSE:SONY) was downgraded by analysts at Macquarie from an “outperform” rating to a “neutral” rating.The current price is $91.35.
SSR Mining (NASDAQ:SSRM) (TSE:SSO) was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $6.00 price target on the stock, down previously from $14.00. This represents a 25.0% upside from the current price of $4.80.
Twilio (NYSE:TWLO) was downgraded by analysts at Northland Securities from an “outperform” rating to a “market perform” rating. They now have a $66.00 price target on the stock. This represents a 7.1% upside from the current price of $61.62.
Westinghouse Air Brake Technologies (NYSE:WAB) was downgraded by analysts at Redburn Atlantic from a “buy” rating to a “neutral” rating. They now have a $135.00 price target on the stock. This represents a 1.2% upside from the current price of $133.35.
United States Steel (NYSE:X) was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $51.00 price target on the stock, up previously from $40.00. This represents a 11.6% upside from the current price of $45.68.
The Wall Street Journal reports that this medical breakthrough is “Transforming Medicine.” One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today’s price.
Alnylam Pharmaceuticals (NASDAQ:ALNY) is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.The current price is $148.75.
Alpine Immune Sciences (NASDAQ:ALPN) is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $44.00 price target on the stock. This represents a 48.0% upside from the current price of $29.73.
argenx (NASDAQ:ARGX) is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.The current price is $391.94.
Cullinan Oncology (NASDAQ:CGEM) is now covered by analysts at Wedbush. They set an “outperform” rating and a $30.00 price target on the stock. This represents a 65.1% upside from the current price of $18.17.
CRISPR Therapeutics (NASDAQ:CRSP) is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.The current price is $84.10.
CervoMed (NASDAQ:CRVO) is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $50.00 price target on the stock. This represents a 212.5% upside from the current price of $16.00.
CervoMed (NASDAQ:CRVO) is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $50.00 price target on the stock. This represents a 212.5% upside from the current price of $16.00.
Cisco Systems (NASDAQ:CSCO) is now covered by analysts at Wells Fargo & Company. They set an “equal weight” rating and a $52.00 price target on the stock. This represents a 6.0% upside from the current price of $49.04.
Deckers Outdoor (NYSE:DECK) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $960.00 price target on the stock. This represents a 11.6% upside from the current price of $860.42.
Dianthus Therapeutics (NASDAQ:DNTH) is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $44.00 price target on the stock. This represents a 82.9% upside from the current price of $24.06.
Eastman Chemical (NYSE:EMN) is now covered by analysts at Redburn Atlantic. They set a “buy” rating and a $110.00 price target on the stock. This represents a 29.9% upside from the current price of $84.68.
Elastic (NYSE:ESTC) is now covered by analysts at Scotiabank. They set a “sector outperform” rating on the stock.The current price is $132.00.
GE HealthCare Technologies (NASDAQ:GEHC) is now covered by analysts at HSBC Holdings plc. They set a “buy” rating and a $100.00 price target on the stock. This represents a 18.2% upside from the current price of $84.61.
Monte Rosa Therapeutics (NASDAQ:GLUE) is now covered by analysts at Wedbush. They set an “outperform” rating and a $11.00 price target on the stock. This represents a 111.5% upside from the current price of $5.20.
Immunovant (NASDAQ:IMVT) is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $55.00 price target on the stock. This represents a 45.3% upside from the current price of $37.85.
Insmed (NASDAQ:INSM) is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $42.00 price target on the stock. This represents a 49.8% upside from the current price of $28.04.
JELD-WEN (NYSE:JELD) is now covered by analysts at Loop Capital. They set a “hold” rating and a $22.00 price target on the stock. This represents a 12.6% upside from the current price of $19.53.
Kymera Therapeutics (NASDAQ:KYMR) is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.The current price is $37.71.
MoonLake Immunotherapeutics (NASDAQ:MLTX) is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $77.00 price target on the stock. This represents a 28.4% upside from the current price of $59.97.
Intellia Therapeutics (NASDAQ:NTLA) is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.The current price is $28.61.
RAPT Therapeutics (NASDAQ:RAPT) is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $39.00 price target on the stock. This represents a 53.0% upside from the current price of $25.49.
Roivant Sciences (NASDAQ:ROIV) is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $17.00 price target on the stock. This represents a 47.4% upside from the current price of $11.53.
Skechers U.S.A. (NYSE:SKX) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $73.00 price target on the stock. This represents a 21.2% upside from the current price of $60.22.
Super Micro Computer (NASDAQ:SMCI) is now covered by analysts at Bank of America Co.. They set a “buy” rating and a $1,040.00 price target on the stock. This represents a 7.8% upside from the current price of $964.74.
Savara (NASDAQ:SVRA) is now covered by analysts at JMP Securities. They set an “outperform” rating and a $8.00 price target on the stock. This represents a 60.3% upside from the current price of $4.99.
Vertex Pharmaceuticals (NASDAQ:VRTX) is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $515.00 price target on the stock. This represents a 21.3% upside from the current price of $424.66.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
Upgrade to MarketBeat All Access and receive your premium edition of MarketBeat Daily at 9:00 AM ET.
UPGRADE NOW
Manage Your Watchlist
View and add up to five holdings to your watchlist.
VIEW MY PORTFOLIO
Join Our Facebook Group
Join MarketBeat’s free stock discussion and trading idea group on Facebook.
JOIN NOW
Thank you for subscribing to MarketBeat!
We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that’s you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
